Tag: Eisai
Eisai & Co and Bliss Biopharmaceutical (Hangzhou) Sign Agreement to Jointly...
Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.
Eisai and Bristol Myers Squibb Sign Global Strategic Collaboration to Jointly...
In a statement released earlier today, Eisai and Bristol-Myers Squibb confirm that the two companies have entered into an exclusive global strategic collaboration agreement...
8th World ADC: Morphotek to Present Preclinical Data on MORAb-202
During the upcoming 8th Annual World ADC being held September 20-22, 2017 at the Sheraton San Diego Marina in San Diego, CA, Morphotek®, a...
